

Accepted Manuscript

Published online: 28 Jun. 2025

Doi: 10.34172/japid.025.3543

Received: 3 May 2024

Revised: 6 June 2025

Accepted: 10 June 2025

Research Article

A pilot study and histological examination of xenograft and autogenous bone combinations with i-PRF in guided bone regeneration

Saurabh Kamat¹ • Senthil Murugan M² • Edlyn Rodrigues¹ • Jochima Eudora Cota^{*3} • Vikas Dhupar¹ • Francis Akkara¹

¹Department of Oral & Maxillofacial Surgery, Goa Dental College and Hospital, India

²Department of Oral & Maxillofacial Surgery, Saveetha Dental College and Hospital, India

³Department of Oral Pathology, Goa Dental College and Hospital, India

***Corresponding Author; Email: jochimacota@gmail.com**
ORCID: <https://orcid.org/0000-0002-6618-9454>

Abstract

Background. This study evaluated the impact of different regenerative biomaterial combinations on bone quality and implant stability in guided bone regeneration (GBR).

Methods. A pilot study was conducted from September 2020 to October 2023 to compare the quality of bone regeneration and implant stability following guided bone regeneration (GBR) using three composite graft combinations. Forty-seven patients participated in the study in three experimental groups: group A (deproteinized cancellous bovine bone [xenograft] with injectable platelet-rich fibrin [i-PRF]), group B (xenograft with autogenous bone graft in a 2:1 ratio with i-PRF), and group C (xenograft with autogenous bone graft in a 1:1 ratio with i-PRF). The implant stability quotient (ISQ) was measured at the time of implant placement. Crestal bone biopsy procedures were performed.

Results. The study found that group C, using a 1:1 ratio of xenograft and autogenous graft with i-PRF, achieved the highest new bone formation (65.83%) and demonstrated moderately high vascularization and osteoclastic activity, indicative of good remodeling potential. ISQ measurements for all groups indicated good primary stability of implants, ranging from 55 to 65 at the time of placement.

Conclusions. Combining xenograft with autogenous graft in a 1:1 ratio, along with i-PRF, yielded optimal outcomes for new bone formation in GBR procedures. However, further research is needed to address the limitations associated with i-PRF, such as lack of rigidity and faster degradation, to enhance its application in GBR procedures.

Key words: Autografts, bone regeneration, dental implant, platelet-rich fibrin.

Introduction

Guided bone regeneration (GBR) is a cornerstone technique in implant dentistry, using barrier membranes to promote selective bone growth in areas of tissue defects near dental implants.^{1,2} By preventing the ingrowth of epithelial and connective tissue cells, GBR fosters bone regeneration while minimizing periodontal infections.^{3,4} Moreover, GBR serves as a well-documented procedure for selective bone formation to regenerate lost alveolar bone anatomy by preventing the ingress of epithelial and connective tissue cells with the help of the cell-occlusive membrane.⁵⁻⁷ While autogenous bone grafts are considered the gold standard due to

their biocompatibility and osteoinductive properties, the discomfort and morbidity associated with harvesting from a separate surgical site have driven the search for alternative strategies. The frequent need for augmenting bone before placing implants, especially in the posterior areas of the upper or lower jaw, has led to the development of bone substitutes.⁸ Clinical and histological evidence supports the efficacy of various biomaterials, including autogenous bone chips, allografts, and xenografts, in addressing bone augmentation needs. Although autologous grafts are biologically safe, they present a myriad of challenges, including the need for additional donor sites and postoperative complications.^{9,10} As alternatives, xenogeneic or alloplastic materials have emerged, meeting criteria such as biocompatibility, osteoconductivity, and resorbability. Notably, deproteinized bovine bone mineral (DBBM), exemplified by BioOss™, exhibits both biocompatibility and osteoconductive properties, proving effective in diverse procedures, encompassing sinus floor augmentation, preservation of the alveolar ridge, and treatment of peri-implant defects.⁹ To optimize the beneficial qualities of each biomaterial, combinations of these materials have been proposed, offering a comprehensive approach to enhancing bone regeneration outcomes in dental implant procedures.¹¹

Research has been done to improve wound healing and bone regeneration in dental procedures by combining bone substitutes with growth factors.^{12,13} Platelet-rich fibrin (PRF), derived from the patient's peripheral blood, contains platelets, leukocytes, and growth factors.¹⁴ Solid and liquid forms of PRF offer flexibility in application.¹⁵ While systematic reviews highlight the positive effects of PRF in dental surgery, particularly in soft tissue and periodontal treatment, its benefits in bone regeneration lack strong evidence.¹⁶

Despite the effectiveness of GBR, the discomfort associated with harvesting autogenous bone grafts prompts the exploration of alternative strategies. This study addresses the need for novel approaches by investigating three regenerative biomaterial combinations in GBR. While various biomaterials have shown promise, including autogenous bone chips, allografts, and xenografts, a consensus on the most effective graft combination remains lacking. This research aims to fill this gap by evaluating the impact of different biomaterial combinations on bone quality and implant stability, contributing new insights to the field.

Methods

A comprehensive study was conducted to compare the quality of bone regeneration and assess implant stability following GBR using three composite graft combinations from September 2020 to October 2023. Forty-seven patients participated in the study, with 88 implants placed. All the patients provided written informed consent. The study received ethical approval from the Dental College & Hospital Institutional Ethics Committee (Ref. No.: GDCH/IEC/III-2020 (11)-PROV).

Inclusion Criteria

- Patients aged 21–75 years
- Patients undergoing delayed implant placements with a maximum of 4 implant threads at the crestal region and requiring GBR

Exclusion Criteria

- Patients with any systemic debilitating conditions such as uncontrolled diabetes mellitus or hypertension
- Patients undergoing immediate implant placements

Study Groups

Patients were randomly assigned to one of the three experimental groups using a computer-generated randomization process. The allocation sequence was concealed in opaque, sealed envelopes, which were opened by the surgical team immediately before the procedure. Randomization ensured even distribution across the groups while accounting for the variability in defect morphology.

Group A (n=14; 25 implants): a composite graft of xenograft and i-PRF

Group B (n=20; 39 implants): a composite graft of xenograft and autogenous graft (2:1 ratio) bound together with i-PRF

Group C (n=13; 24 implants): a composite graft of xenograft and autogenous graft (1:1 ratio) bound together using i-PRF

The rationale for selecting the 2:1 and 1:1 ratio in groups B and C was based on prior evidence suggesting improved osteoconductive properties with higher autogenous bone proportions, balanced against the potential for donor site morbidity.

Surgical Procedure

Before the procedures, the patients received stringent antibiotic prophylaxis (amoxicillin, 500 mg, and clavulanic acid, 125 mg - Augmentin, provided by GlaxoSmithKline Malta Ltd., Malta).¹⁷ The antibiotic prophylaxis was initiated one hour before the surgery and continued at regular intervals postoperatively for 120 hours. Implant osteotomies were performed with precision, and ISQ measurements were taken using the Penguin RFA unit (Integration Diagnostics, Sweden AB) at the time of implant placement. Buccal bone decortication was performed to optimize the regenerative process.

Bone Graft and Membrane Use

A resorbable membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland) was used. Graft combinations were prepared as follows: xenograft and i-PRF for group A, xenograft, autogenous graft (2:1 ratio), and i-PRF for group B, and xenograft, autogenous graft (1:1 ratio), and i-PRF for group C. Graft volumes were measured using the technique described by Delvin et al.¹⁸ The i-PRF was freshly prepared using patients' own blood and centrifuged at 700 rpm for 3 mins in test tubes without anticoagulants. Autogenous bone scrapes were obtained using a Buser scraper (HuFriedy Group) either from the apical areas of the same surgical site or from a donor site (external oblique ridge).

Following the surgical procedure, the patients underwent a healing phase that lasted approximately 4 months. Re-entry was performed for abutment placement, with an indentation mark made at the implant site to guide sample collection. Bone samples (an average diameter of 2.5 mm and a length of 10 mm) were obtained using a #21 blade from implant beds. The samples were fixed in 10% buffered formalin, and tissue decalcification was achieved using a solution containing formic acid, formaldehyde, and deionized water (Decalcifier-Fixative Gooding Stewart, Bio-Optica Milano s.p.a). Sections of 4–7-µm thickness were prepared and stained with Hematoxylin and Eosin (H&E) for histological examination under light microscopy at ×400 magnification coupled with Image Access software (Imagic, Glattbrugg, Switzerland).

Histological Evaluation

Randomly chosen fields were evaluated for new bone volume and residual graft material, and the presence of vascularization, osteoblasts/osteoclasts, and granulocytes was assessed. Vascularization was determined by observing new vessel formation around and within graft material and newly formed bone. The surgeon performed all implant placements, and all study personnel and patients were aware of group assignments. Histomorphometric variables measured bone vitality, remodeling, and maturity, including new bone volume and residual

graft material. The histometric analysis was conducted by an examiner trained in histology, using a 400× magnification and a calibrated grid eyepiece.

Statistical Analysis

Statistical analysis was performed using SPSS, where data were entered into Microsoft Excel. Descriptive statistics were applied. Comparative analyses between study groups involved Fisher's exact test and one-way ANOVA, followed by post hoc Tukey tests. A significance threshold of $P < 0.05$ was considered statistically significant.

Results

Table 1 presents the individual responses within each group. Table 2 compares all the groups in terms of new bone formation and residual graft material. Substantial variations were observed in new bone formation and the percentages of residual graft material. Group C exhibited the highest new bone formation (65.83%), significantly outperforming groups A (19.00%) and B (39.62%; $P < 0.001$). Additionally, group A had the highest residual graft material percentage (57.20%), significantly surpassing groups B (35.26%) and C (20.65%; $P < 0.001$; Figure 1).

Pairwise comparisons between study groups using post hoc Tukey tests are tabulated in Table 3. However, in terms of the percentage of new bone formation, all pairwise comparisons revealed statistically significant differences ($P < 0.001$). Group A exhibited significantly lower new bone formation compared to groups B and C. In contrast, group B also had significantly lower new bone formation than group C. Group A exhibited significantly more residual graft material than groups B and C ($P < 0.001$), with group C having the least.

Table 4 presents a comprehensive analysis of vascularization and osteoclastic activity across the study groups. Significant differences were observed in vascularization ($P = 0.001$), with the percentage of a low degree of vascularization (+/-) decreasing from 100.0% in group A to 66.7% in group C. In the moderately high degree of vascularization (++) category, group C stood out with a rate of 33.3%. For osteoclastic activity, significant differences were found with similar percentages in the mild osteoclastic activity (+) category (72.0%, 76.9%, and 75.0% for groups A, B, and C, respectively). Group C did not exhibit low osteoclastic activity (+/-), while groups A and B showed 28.0% and 23.1% of low osteoclastic activity, respectively. Only group C exhibited moderately high osteoclastic activity (++), probably suggestive of remodeling. ISQ measurements for all groups indicated good primary stability of implants, ranging from 55 to 65 at the time of placement and above 75 at second-stage surgery (secondary stability).

Discussion

Our pilot study demonstrated that the optimal outcome for new bone formation (65.83%) was achieved through the combination of xenograft and autogenous bone graft in a 1:1 ratio with i-PRF. This finding is consistent with the traditional use of autogenous bone graft, considered the gold standard due to its cellular and molecular elements that support osteogenesis.¹⁹ Allogenic grafts have shown promise, offering mechanical properties comparable to those of autologous bone despite lacking viable cells and retaining the collagenous matrix and natural bone proteins.²⁰ However, they also lack important properties needed for a GBR scaffold, such as mechanical strength and volume maintenance due to slow resorption.

Contrary to our findings, a clinical study using allogenic graft reported lower mean values of new bone in the combination group (allografts with autograft) compared to the group with allogeneic graft alone (35% and 39%).²¹ However, no significant difference between the groups was observed, possibly due to variations in the ratio of autogenous bone grafts used, which was 30%²¹ and 50%.²²

Regarding graft resorption rates, our findings showed that group C exhibited a moderately high degree of osteoclastic activity. Reports indicate a wide range of autogenous bone graft resorption rates (12% to 80%).²³ In contrast to our study, two clinical studies using allogeneic graft reported higher rates of resorption in the combined group compared to allogeneic bone graft alone, without significant differences.^{22,24}

Furthermore, deproteinized cancellous bovine bone with i-PRF showed a significant 57.20% residual graft material, indicating a slower resorption rate compared to xenografts with autogenous bone graft in a 2:1 ratio. Graft proportions have been a subject of discussion in GBR, with different studies using a different autogenous graft to allogeneic graft ratios, such as 50/50%²² and 30/70%,²¹ highlighting the lack of agreement in the field. Histological analysis from various studies has presented mixed results regarding new bone formation when combining autogenous and allogeneic bone grafts.

Finally, group C in our study demonstrated the highest degree of vascularization (++). The moderately high osteoclastic activity in group C indicates good remodeling and, thus, a higher potential for faster replacement of the xenogeneic scaffold with vital new bone.

In our study, all the groups used i-PRF. Notably, two clinical studies^{25,26} exclusively using PRF for maxillary sinus augmentation demonstrated significant bone gain. Specifically, one case report in a 59-year-old patient showed dense bone-like tissue formation around implants, accompanied by evidence of osteocytes and osteoblasts.²⁵ However, when compared to other materials such as hydroxyapatite²⁷ and autogenous bone grafting,²⁸ PRF did not show significant advantages in promoting osteogenesis. Although PRF may enhance osteogenesis, its limitations, including lack of rigidity and faster degradation,²⁹ underscore the need for further research to improve its application in dental procedures.

The study's limitations include the lack of information on modifying factors for osseointegration and GBR success, such as smoking history and a history of periodontitis. Additionally, the study did not address potential confounding variables such as the presence of systemic debilitating conditions like uncontrolled diabetes mellitus or hypertension, etc. Furthermore, while the study evaluated three regenerative biomaterial combinations in GBR, it did not explore other potential combinations or variations in surgical techniques that could affect outcomes. Therefore, the findings of the study should be interpreted within the context of these limitations, and future research should aim to address these gaps.

Conclusions

This pilot study demonstrated that combining xenograft with autogenous bone in a 1:1 ratio and i-PRF resulted in superior bone regeneration in GBR. These findings support the use of balanced graft compositions to enhance biological and mechanical outcomes. Further studies are needed to optimize PRF-based protocols for clinical use.

Acknowledgments

We would like to express our sincere gratitude to the patients who participated in this study, making valuable contributions to the advancement of knowledge in implant dentistry. We also extend our sincere appreciation to Dr. Meet Shah and Dr. Ashwin Mysore for their valuable insights and support throughout the course of this research.

Authors' Contributions

Conceptualization: Saurabh Kamat, Senthil Murugan M, Edlyn Rodrigues, Jochima Eudora Cota, Vikas Dhupar, and Francis Akkara

Methodology: Saurabh Kamat, Senthil Murugan M, Edlyn Rodrigues, Jochima Eudora Cota, Vikas Dhupar, and Francis Akkara

Validation: Saurabh Kamat

Formal analysis: Saurabh Kamat, Senthil Murugan M, Edlyn Rodrigues, Jochima Eudora Cota, Vikas Dhupar, and Francis Akkara
Investigation: Saurabh Kamat and Jochima Eudora Cota
Resources: Saurabh Kamat, Senthil Murugan M, Edlyn Rodrigues, Jochima Eudora Cota, Vikas Dhupar, and Francis Akkara
Data curation: Senthil Murugan M, Edlyn Rodrigues, Jochima Eudora Cota, Vikas Dhupar, and Francis Akkara
Project administration: Saurabh Kamat
Funding acquisition: Saurabh Kamat
Visualization: Saurabh Kamat
Supervision: Vikas Dhupar and Francis Akkara
Writing—original draft: Saurabh Kamat
Writing—review and editing: Saurabh Kamat, Senthil Murugan M, Edlyn Rodrigues, Jochima Eudora Cota, Vikas Dhupar, and Francis Akkara

Competing Interests

The authors declare that they have no competing interests.

Consent for Publication

Not applicable.

Availability of Data

All data generated and analyzed during this study are included in this published article.

Ethics Approval

Ethical approval was obtained from the Dental College & Hospital Institutional Ethics Committee (Ref. No.: GDCH/IEC/III-2020 (11)-PROV).

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Retzepi M, Donos N. Guided bone regeneration: biological principle and therapeutic applications. *Clin Oral Implants Res.* 2010;21:567–76. doi:10.1111/j.1600-0501.2010.01922.x
2. Donos N, Angelov N, Padhye N, Sculean A, Calciolari E. Bone regeneration in implant dentistry: which are the factors affecting the clinical outcome? *Periodontol* 2000. 2023;24. doi:10.1111/prd.12518
3. Cho KS, Choi SH, Han KH, Chai JK, Wikesjö UM, Kim CK. Alveolar bone formation at dental implant dehiscence defects following guided bone regeneration and xenogeneic freeze-dried demineralized bone matrix. *Clin Oral Implants Res.* 1998;9:419–28. doi:10.1034/j.1600-0501.1996.090607.x
4. Liu J, Kerns DG. Mechanisms of guided bone regeneration: a review. *Open Dent J.* 2014;8:56–65. doi:10.2174/1874210601408010056
5. Nyman S, Lang NP, Buser D, Bragger U. Bone regeneration adjacent to titanium dental implants using guided tissue regeneration: a report of two cases. *Int J Oral Maxillofac Implants.* 1990;5(1):9–14
6. Aghaloo TL, Moy PK. Which hard tissue augmentation techniques are the most successful in furnishing bony support for implant placement? *Int J Oral Maxillofac*

- Implants. 2007;22 Suppl:49–70. Erratum in: *Int J Oral Maxillofac Implants*. 2008;23(1):56
7. Dahlin C, Linde A, Gottlow J, Nyman S. Healing of bone defects by guided tissue regeneration. *Plast Reconstr Surg*. 1988;81(5):672–6. doi:10.1097/00006534-198805000-00004
 8. Idiri K, Bousnane I, Soueidan A, Verner C, Renard E, Struillou X. The effectiveness of the addition of platelet-rich fibrin to bovine xenografts in sinus and bone ridge augmentation: a systematic review. *J Funct Biomater*. 2023;14(7):389. doi:10.3390/jfb14070389
 9. Zhao R, Yang R, Cooper PR, Khurshid Z, Shavandi A, Ratnayake J. Bone grafts and substitutes in dentistry: a review of current trends and developments. *Molecules*. 2021;26. doi:10.3390/molecules26103007
 10. Danesh-Sani SA, Loomer PM, Wallace SS. A comprehensive clinical review of maxillary sinus floor elevation: anatomy, techniques, biomaterials and complications. *Br J Oral Maxillofac Surg*. 2016;54:724–30. doi:10.1016/j.bjoms.2016.05.008
 11. Temmerman A, Cleeren K, Van Dessel J, De Greef A, Jacobs R, Dhondt R. Bovine-derived xenograft in combination with autogenous bone chips versus xenograft alone for the augmentation of bony dehiscences around oral implants: a randomized, controlled, split-mouth clinical trial. *J Clin Periodontol*. 2020;47:110–9. doi:10.1111/jcpe.13209
 12. Oliveira ER, Nunes L, Podstawczyk D, Allahbakhsh A, Ratnayake J, Brasil DL, et al. Advances in growth factor delivery for bone tissue engineering. *Int J Mol Sci*. 2021;22. doi:10.3390/ijms22020903
 13. Gillman CE, Jayasinghe SN. FDA-approved bone grafts and bone graft substitute devices in bone regeneration. *Mater Sci Eng C Mater Biol Appl*. 2021;130:112466. doi:10.1016/j.msec.2021.112466
 14. Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunité en parodontologie: Le PRF. *Implantodontie*. 2001;42:55–62
 15. Thanasisuebwong P, Surarit R, Bencharit S, Ruangsawasdi N. Influence of fractionation methods on physical and biological properties of injectable platelet-rich fibrin: an exploratory study. *Int J Mol Sci*. 2019;20. doi:10.3390/ijms20071657
 16. Miron RJ, Zhang Y, Pikos MA, Salama M, Lee S, Guillemette V, et al. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. *Clin Oral Investig*. 2017;21:1913–27. doi:10.1007/s00784-017-2133-z
 17. Gallo P, De Angelis D, Di Berardino S, Papi A, Mencio M, Turrini HA, et al. Comparative analysis of two biomaterials mixed with autogenous bone graft for vertical ridge augmentation: a histomorphometric study in humans. *Clin Implant Dent Relat Res*. 2022;24(5):709–19. doi:10.1111/cid.13124
 18. Devlin MF, Rohan R, Jones R, Ayoub AF. A sample method of measuring bone graft volume: technical note. *J Craniomaxillofac Surg*. 2003;31(1):40–1. doi:10.1016/s1010-5182(02)00167-1
 19. Chavda S, Levin L. Human studies of vertical and horizontal alveolar ridge augmentation comparing different types of bone graft materials: a systematic review. *J Oral Implantol*. 2018;44:74–84. doi:10.1563/aaaid-joi-D-17-00053
 20. Sanz M, Donos N, Apatzidou D, Artzi Z, Bozic D, Calciolari E. Biomaterials and regenerative technologies used in bone regeneration in the craniomaxillofacial region: consensus report of group 2 of the 15th European Workshop on Periodontology on Bone Regeneration. *J Clin Periodontol*. 2019;46:82–91. doi:10.1111/jcpe.13123
 21. Patel A, Gohil H, Hill M, Shumway B, Radmall A. Ridge augmentation comparing an allograft plus autogenous bone chips to an osteoinductive demineralized bone matrix:

- a clinical and histologic study in humans. *Implant Dent.* 2019;28:613–20. doi:10.1097/ID.0000000000000925
22. Hashemipoor M, Aghaloo N, Mohammadi M, Kalantari M, Arabsolghar M, Ranjbar H. Radiological and histological evaluation of horizontal ridge augmentation using corticocancellous freeze-dried bone allograft with and without autogenous bone: a randomized controlled clinical trial. *Clin Implant Dent Relat Res.* 2020;22:582–92. doi:10.1111/cid.12935
 23. Starch-Jensen T, Becktor JP. Maxillary alveolar ridge expansion with split-crest technique compared with lateral ridge augmentation with autogenous bone block graft: a systematic review. *J Oral Maxillofac Res.* 2019;10(4):e2. doi:10.5037/jomr.2019.10402
 24. Beitlitum I, Artzi Z, Nemcovsky CE. Clinical evaluation of particulate allogeneic with and without autogenous bone grafts and resorbable collagen membranes for bone augmentation of atrophic alveolar ridges. *Clin Oral Implants Res.* 2010;21:1242–50. doi:10.1111/j.1600-0501.2010.01936.x
 25. Zhao JH, Tsai CH, Chang YC. Clinical application of platelet-rich fibrin as the sole grafting material in maxillary sinus augmentation. *J Formos Med Assoc.* 2015;114:779–80. doi:10.1016/j.jfma.2015.02.009
 26. Kanayama T, Horii K, Shibuya Y. Crestal approach to sinus floor elevation for atrophic maxilla using platelet-rich fibrin as the only grafting material. *Implant Dent.* 2016;25:32–8. doi:10.1097/ID.0000000000000327
 27. Dutta S, Panda P, Singh S, Sharma M, Singh M, Srivastava D. A randomized comparative prospective study of platelet-rich plasma, platelet-rich fibrin, and hydroxyapatite as a graft material for mandibular third molar extraction socket healing. *Natl J Maxillofac Surg.* 2016;7(1):45–51. doi:10.4103/0975-5950.196124
 28. Galav S, Chaturvedi R, Mishra V, Tripathi R, Agarwal R, Galav A. Comparative evaluation of platelet-rich fibrin and autogenous bone graft for the treatment of infrabony defects in chronic periodontitis: clinical, radiological, and surgical re-entry. *Indian J Dent Res.* 2016;27(5):502. doi:10.4103/0970-9290.195634
 29. Sam G, Verma R, Amol N. In vitro evaluation of mechanical properties of platelet-rich fibrin membrane and scanning electron microscopic examination of its surface characteristics. *J Indian Soc Periodontol.* 2015;19(1):32–6. doi:10.4103/0972-124X.145821

Table 1: Patient data in all study groups

Groups	Patient No.	Tooth No.	New bone formation (%)	Residual graft material (%)	Vascularization	Osteoclastic activity
Group A	1	5	20	55	+	+
		6	15	65	+	+
		7	20	50	+	+
	2	21	10	70	+	+
		22	15	60	+	+
	3	9	25	50	+	+
	4	8	35	40	+	+/-
	5	26	15	65	+	+
		27	15	65	+	+
		28	20	55	+	+
	6	3	25	45	+	+
		4	20	60	+	+
	7	14	25	65	+	+/-
		15	20	50	+	+/-
	8	22	10	75	+	+
		24	15	70	+	+
		26	10	65	+	+
	9	27	15	55	+	+/-
	10	12	15	55	+	+
	11	7	20	60	+	+
	12	12	25	50	+	+/-
		13	25	55	+	+/-
		14	20	50	+	+/-
	13	29	15	40	+	+
	14	28	25	60	+	+
Group B	1	10	35	45	+	+
	2	12	35	40	+	+
		13	45	30	+	+
	3	6	50	25	+	+
		7	40	25	+	+
	4	27	45	25	+	+
		28	40	30	+	+
	5	20	35	55	++	+/-
		21	30	55	++	+/-
		22	35	40	++	+/-
	6	19	30	45	+	+
		20	35	40	+	+
	7	8	40	30	+	+
	8	30	40	25	+	+
	9	22	45	30	+	+/-
		24	45	25	+	+/-
		26	45	40	+	+/-
	10	10	30	40	+	+
		11	30	45	+	+
		12	40	30	+	+
	11	7	35	40	+	+
	12	10	35	40	+	+

		11	40	30	+	+
		12	35	35	+	+
	13	12	40	35	+	+
		13	45	35	+	+
	14	28	55	30	+	+
		29	60	25	+	+
	15	19	50	35	+	+/-
		20	45	30	+	+/-
		21	35	35	+	+/-
	16	27	40	35	+	+
		24	40	30	+	+
	17	4	40	35	+	+
		6	35	40	+	+
		7	40	40	+	+
	18	13	30	35	+	+
	19	5	35	40	+	+
	20	9	40	30	+	+
Group C	1	6	80	10	+	+
		8	75	15	+	+
	2	10	65	25	++	+
		12	70	15	++	+
	3	19	65	15	+	+
	4	3	60	25	+	+
		4	70	30	+	+
	5	19	65	20	++	++
		20	65	25	++	++
		21	60	30	++	++
	6	6	55	25	++	++
		4	65	20	++	++
		3	65	25	++	++
	7	27	60	20	+	+
		25	75	10	+	+
	8	5	70	15	+	+
	9	12	65	10	+	+
	10	29	55	35	+	+
		30	65	25	+	+
	11	8	70	20	+	+
		6	55	25	+	+
	12	21	65	25	+	+
		19	70	20	+	+
	13	27	70	15	+	+
		29				

+ mild (10% to 30% of the microscopic field); ++ moderately high (30% to 60% of the microscopic field); +/- low (< 10% of the microscopic field); - not present

Table 2: Comparison of new bone formation and residual graft material between the study groups

Variable	Study groups	N	Mean	SD	Min	Max	ANOVA	
							F	P-value
New bone formation (%)	A	25	19.00	5.951	10	35	322.70	<0.001*
	B	39	39.62	6.823	30	60		
	C	24	65.83	6.370	55	80		
Residual graft material (%)	A	25	57.20	9.138	40	75	132.23	<0.001*
	B	39	35.26	7.604	25	55		
	C	23	20.65	6.793	10	35		

*P<0.05 Statistically significant; P>0.05 Non-significant, NS

Table 3: Pairwise comparison of new bone formation and residual graft material between the study groups

Variable	Comparison group 1	Comparison group 2	Mean difference	SD	P-value	95% confidence interval	
						Lower bound	Upper bound
New bone formation (%)	A	B	-20.62	1.66	<0.001*	-24.57	-16.66
		C	-46.83	1.85	<0.001*	-51.24	-42.43
	B	C	-26.22	1.68	<0.001*	-30.22	-22.22
Residual graft material (%)	A	B	21.94	2.02	<0.001*	17.13	26.76
		C	36.55	2.28	<0.001*	31.12	41.98
	B	C	14.60	2.07	<0.001*	9.66	19.55

*P<0.05 Statistically significant; P>0.05 Non-significant, NS

Table 4: Post hoc Tukey tests comparing histological parameters between the groups

Variable	Grading of histological activity	Study groups			Total	Fisher's exact test
		A	B	C		P-value
Vascularization	+	25	36	16	77	0.001*
		100.0%	92.3%	66.7%	87.5%	
	++	0	3	8	11	
		0.0%	7.7%	33.3%	12.5%	
Osteoclastic Activity	+	18	30	18	66	<0.001*
		72.0%	76.9%	75.0%	75.0%	
	+/-	7	9	0	16	
		28.0%	23.1%	0.0%	18.2%	
	++	0	0	6	6	
		0.0%	0.0%	25.0%	6.8%	

*P<0.05 Statistically significant, P>0.05 Non-significant, NS

+ mild (10% to 30% of the microscopic field); ++ moderately high (30% to 60% of the microscopic field); +/- low (< 10% of the microscopic field); - not present




Figure 1. Histological sections showing (a) xenograft with i-PRF, (b) xenograft with autogenous bone graft (2:1) and i-PRF, and (c) xenograft with autogenous bone graft (1:1) and i-PRF.

Staining: H&E; Magnification: 400x.

1: Connective tissue; 2: Bio-Oss; 3: Bone.